NanoViricides Inc. (NNVC)

[changes_iv]

Our small company, NanoViricides, Inc., is very frugal...

Nanomedicines of the future

The advances in nanomedicine that were announced in 2013 show how this pioneering field is a strong weapon in improving how we diagnose, treat and understand diseases. As we are at such an early stage in developing nanomedicines, our knowledge and insight can only grow driving further advances that could see us make real headway in treating some of the world's most deadly diseases.

Hundreds of millions of pounds have already been invested in research in this field, and the global nanaomedicine market has been forecast to grow by 12.3 per cent a year up to 2016. Worldwide, physical and biological scientists, clinicians and healthcare professionals are excited about what it could potentially deliver. As healthcare moves from a one-size-fits-all treatment approach to more personalized care based on an individual's genetics and immune responses, nanomedicine is going to be the key to providing the tailored treatment that will improve patient care.

One of the biggest problems that nanomedicines faces is the enormous costs involved in getting the products approved and to the market. But as the big players, GlaxoSmithKline, Pfizer and Abbott Laboraties, and others of that ilk, are leading the way with bringing nanomedicines to market, they have the big budgets that can support it.

As we look ahead to the nanomedicines of the future, everyone's getting excited about the possibility of medical nanorobots, which coud be used to perform surgery on individual cells and seek out cancer cells and eliminate them. But before we can create nanorobots we have to create a new technology: molecular manufacturing. Perhaps in this field lies the next breakthrough announcement that we can expect from the nanomedicine research world.